Novo said Teva could launch its generic earlier, but not before March of 2023, unless the Victoza patents are no longer in force or there is another generic on the market. Novo could also get a ...
The Victoza approval comes after a priority review by the FDA, and shortly after Novo Nordisk reported the results of the phase 3 ELLIPSE trial which showed the drug was able to reduce haemoglobin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback